We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PRPO:NASDAQPrecipio, Inc. Analysis

Data as of 2026-06-18 - not real-time

$22.36

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Precipio trades near its 20‑day SMA, which sits just below the 200‑day SMA, suggesting a neutral price bias. The 14‑day RSI is in the lower third of its range, hinting at modest downside pressure but also room for a rebound. A bullish MACD histogram, albeit small, indicates a potential short‑term upside momentum. Volatility is elevated at over 45% on a 30‑day basis, while beta remains low, reflecting high price swings that are not strongly correlated with the broader market. The stock’s forward PE of roughly 57× dwarfs the industry average of 24×, and the discounted cash‑flow model values the company at just over $1, far below the current market price of $22, flagging a significant overvaluation. Meanwhile, the company reports negative operating and profit margins, modest cash generation, and a decreasing volume trend, all of which temper optimism.
Fundamentally, the firm’s revenue growth is strong but not enough to offset ongoing losses and a high debt‑to‑equity ratio. The lack of dividend and a weak free cash flow profile further limit income‑oriented appeal. Technical support sits near $21.4, with resistance around $25.6, framing a relatively narrow trading range. Given the combination of high valuation, negative earnings, and elevated volatility, the outlook leans toward caution, with a bias toward holding rather than adding new positions.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical support level
  • Bullish MACD histogram
  • High short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Significant overvaluation relative to DCF
  • Negative operating margins and cash flow
  • Decreasing volume trend

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained earnings losses and high PE
  • Weak balance‑sheet metrics
  • DCF valuation far below market price

Key Metrics & Analysis

Financial Health

Revenue Growth36.20%
Profit Margin-3.57%
P/E Ratio57.3
ROE-7.13%
ROA-5.74%
Debt/Equity24.65
P/B Ratio2.8
Op. Cash Flow$793.0K
Free Cash Flow$84.8K
Industry P/E24.3

Technical Analysis

TrendNeutral
RSI37.4
Support$21.37
Resistance$25.60
MA 20$23.12
MA 50$26.46
MA 200$23.58
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Fair Value$1.23
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.26
Volatility47.36%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.